We assessed [18F]FDG PET uptake and tumor volume in trastuzumab-sensitive and trastuzumab-resistant HER-2-overexpressing tumor xenografts after treatment for 2 and 7 days with PI3K/Akt/mTOR targeted drugs. The gene discussed is AKT1; the disease is neoplasm.